We report a case series of three women with advanced-stage low-grade serous carcinoma harboring <i>RAS</i> mutation who had stabilization of their disease during several months under targeted therapy combining anti-EGFR antibody and MEK inhibitor. Here, MAP2K7 is linked to serous adenocarcinoma.